IDXX · Idexx Laboratories Inc /De
$586.67
-3.33 (-0.56%)
At close · Aug 7
Market Cap
$46.22B
Shares
78.78M
Idexx Laboratories Inc Earnings Call Transcripts
Every quarterly earnings call for Idexx Laboratories Inc (IDXX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲3.9%
$841.66M
$180.94M
'22 Q3
22-11-01
▲3.4%
$828.57M
$172.21M
'22 Q4
23-02-06
▲7.6%
$900.20M
$214.05M
'23 Q1
23-05-02
▲9.7%
$943.63M
$224.24M
'23 Q2
23-08-01
▲8.8%
$915.53M
$212.23M
'23 Q3
23-11-01
▲8.8%
$901.60M
$194.52M
'23 Q4
24-02-05
▲7.1%
$964.10M
$235.58M
'24 Q1
24-05-01
▲6.4%
$1.00B
$203.30M
'24 Q2
24-08-06
▲6.6%
$975.54M
$232.84M
'24 Q3
24-10-31
▲5.8%
$954.29M
$216.15M
'24 Q4
25-02-03
▲3.6%
$998.43M
$242.68M
'25 Q1
25-05-01
▲10.6%
$1.11B
$293.99M
'25 Q2
25-08-04
▲13.3%
$1.11B
$274.61M
'25 Q3
25-11-03
▲14.3%
$1.09B
$248.19M
'25 Q4
26-02-02
▲14.3%
$1.14B
$278.45M
'26 Q1
26-05-05
LATEST
▲9.7%
$1.22B
$338.41M
'26 Q2
26-08-04
Capital Markets Day
Investor event
2026-08-13
IDEXX Investor Day 2026
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Second Quarter 2026 Earnings Conference Call
Confident tone
CAG Diagnostics Recurring Revenue
Premium Instrument Placements & InView DX
International Growth
Revenue
$1.22B
▲ 9.7% YoY Diluted EPS
$4.27
▲ 17.6% YoY Gross margin
64.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Idexx Laboratories Inc /De Q1 FY2026 Earnings Call
Confident tone
Companion Animal Diagnostics (CAG) Recurring Revenue
Guidance Raise / Full-Year Outlook
Premium Instrument Placements
Revenue
$1.14B
▲ 14.3% YoY Diluted EPS
$3.47
▲ 17.2% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-02
Idexx Laboratories Inc /De Q4 FY2025 Earnings Call
Confident tone
Premium Instrument Placements (InVue DX, Catalyst, etc.)
Software / SaaS (Velo, PIMs)
2026 Financial Guidance and Margin Expansion
Revenue
$1.09B*
▲ 14.3% YoY Gross margin
60.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Idexx Laboratories Inc /De Q3 FY2025 Earnings Call
Confident tone
IDEXX Cancer Dx Adoption
Premium Instrument Placements and Installed Base
CAG Diagnostics Recurring Revenue Growth
Revenue
$1.11B
▲ 13.3% YoY Diluted EPS
$3.40
▲ 21.4% YoY Gross margin
61.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Idexx Laboratories Inc /De Q2 FY2025 Earnings Call
Confident tone
CAG Diagnostic Recurring Revenue Growth
IDEXX Cancer Dx Launch
Profitability and Margin Expansion
Revenue
$1.11B
▲ 10.6% YoY Diluted EPS
$3.63
▲ 48.8% YoY Gross margin
62.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Idexx Laboratories Inc /De Q1 FY2025 Earnings Call
Positive tone
IDEXX inVue Dx platform launch
U.S. clinical visit headwinds
Organic revenue growth and execution
Revenue
$998.43M
▲ 3.6% YoY Diluted EPS
$2.96
▲ 5.3% YoY Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-03
Idexx Laboratories Inc /De Q4 FY2024 Earnings Call
Confident tone
Organic revenue growth
Innovation / new product launches
Operating margin and gross margin
Revenue
$954.29M*
▲ 5.8% YoY Gross margin
59.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Idexx Laboratories Inc /De Q3 FY2024 Earnings Call
Positive tone
CAG diagnostic recurring revenue
IDEXX In View / In Vue analyzer launch
US macro and sector headwinds
Revenue
$975.54M
▲ 6.6% YoY Diluted EPS
$2.80
▲ 10.7% YoY Gross margin
61.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Idexx Laboratories Inc /De Q2 FY2024 Earnings Call
Positive tone
Innovation and inVue launch
CAG diagnostic recurring revenue
U.S. clinical visit headwinds
Revenue
$1.00B
▲ 6.4% YoY Diluted EPS
$2.44
▼ 8.6% YoY Gross margin
61.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Idexx Laboratories Inc /De Q1 FY2024 Earnings Call
Positive tone
CAG Diagnostic recurring revenue growth
Premium instrument placements and installed base
U.S. clinical visit softness and macro headwinds
Revenue
$964.10M
▲ 7.1% YoY Diluted EPS
$2.81
▲ 10.2% YoY Gross margin
61.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-05
Idexx Laboratories Inc /De Q4 FY2023 Earnings Call
Confident tone
CAG Diagnostic Recurring Revenue Growth
Veterinary Software and Diagnostic Imaging
2024 Financial Guidance
Revenue
$901.60M*
▲ 8.8% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Idexx Laboratories Inc /De Q3 FY2023 Earnings Call
Revenue
$915.53M
▲ 8.8% YoY Diluted EPS
$2.53
▲ 17.7% YoY Gross margin
59.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Idexx Laboratories Inc /De Q2 FY2023 Earnings Call
Revenue
$943.63M
▲ 9.7% YoY Diluted EPS
$2.67
▲ 71.2% YoY Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Idexx Laboratories Inc /De Q1 FY2023 Earnings Call
Revenue
$900.20M
▲ 7.6% YoY Diluted EPS
$2.55
▲ 12.3% YoY Gross margin
60.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-06
Idexx Laboratories Inc /De Q4 FY2022 Earnings Call
Revenue
$828.57M*
▲ 3.4% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Idexx Laboratories Inc /De Q3 FY2022 Earnings Call
Revenue
$841.66M
▲ 3.9% YoY Diluted EPS
$2.15
▲ 5.9% YoY Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Idexx Laboratories Inc /De Q2 FY2022 Earnings Call
Revenue
$860.55M
▲ 4.2% YoY Diluted EPS
$1.56
▼ 33.3% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Idexx Laboratories Inc /De Q1 FY2022 Earnings Call
Revenue
$836.55M
▲ 7.6% YoY Diluted EPS
$2.27
▼ 3.4% YoY Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
Idexx Laboratories Inc /De Q4 FY2021 Earnings Call
Revenue
$801.09M*
▲ 11.1% YoY Gross margin
57.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Idexx Laboratories Inc /De Q3 FY2021 Earnings Call
Revenue
$810.42M
▲ 12.3% YoY Diluted EPS
$2.03
▲ 20.1% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-30
Idexx Laboratories Inc /De Q2 FY2021 Earnings Call
Revenue
$826.14M
▲ 29.6% YoY Diluted EPS
$2.34
▲ 36% YoY Gross margin
59.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Idexx Laboratories Inc /De Q1 FY2021 Earnings Call
Revenue
$777.71M
▲ 24.2% YoY Diluted EPS
$2.35
▲ 82.2% YoY Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-02
Idexx Laboratories Inc /De Q4 FY2020 Earnings Call
Revenue
$720.94M*
▲ 19.1% YoY Gross margin
56.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Idexx Laboratories Inc /De Q3 FY2020 Earnings Call
Revenue
$721.79M
▲ 19.2% YoY Diluted EPS
$1.69
▲ 36.3% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Idexx Laboratories Inc /De Q2 FY2020 Earnings Call
Revenue
$637.59M
▲ 2.8% YoY Diluted EPS
$1.72
▲ 20.3% YoY Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Idexx Laboratories Inc /De Q1 FY2020 Earnings Call
Revenue
$626.34M
▲ 8.7% YoY Diluted EPS
$1.29
▲ 10.3% YoY Gross margin
57.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-31
Idexx Laboratories Inc /De Q4 FY2019 Earnings Call
Revenue
$605.45M
▲ 10.2% YoY Diluted EPS
$1.04
▲ 6.1% YoY Gross margin
54.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
874716
CUSIP
45168D104
13F (30d)
684 filings
655 filers
Visit website
Investor relations